Neuronetics Secures Up To $60 Million in New Debt Financing with SLR Capital Partners, Provides Greenbrook TMS with $6.0 Million Promissory Note
MALVERN, Pa., April 04, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage…
MALVERN, Pa., April 04, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage…
MALVERN, Pa., April 04, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage…
Clinical Trial Focuses on Assessing Whether LB-100 Enhances the Effectiveness of a Standard Regimen Combining…
Clinical Trial Focuses on Assessing Whether LB-100 Enhances the Effectiveness of a Standard Regimen Combining…
Roll-Out Across National Bioskills Training Centers Gives Med Device Companies and Surgeons Access to Intelligent…
Roll-Out Across National Bioskills Training Centers Gives Med Device Companies and Surgeons Access to Intelligent…
BOSTON, April 04, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare…
BOSTON, April 04, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare…
In the final report, sabizabulin significantly reduced key cytokines involved in Acute Respiratory Distress Syndrome…
The Tel Aviv Sourasky Medical Center granted its final approval to use SCI-110 in a…
In the final report, sabizabulin significantly reduced key cytokines involved in Acute Respiratory Distress Syndrome…
Company to Host Open House to Celebrate Official Launch of Newest CGMP Mammalian Cell Manufacturing…
The Tel Aviv Sourasky Medical Center granted its final approval to use SCI-110 in a…
Company to Host Open House to Celebrate Official Launch of Newest CGMP Mammalian Cell Manufacturing…
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will…
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will…
— Children aged 5 to 17 with autism are now eligible to enroll in the…
Clinical collaboration with BeiGene announced on April 3, 2023 to evaluate the safety and efficacy…
— Children aged 5 to 17 with autism are now eligible to enroll in the…
Clinical collaboration with BeiGene announced on April 3, 2023 to evaluate the safety and efficacy…